{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:41:17Z","timestamp":1757572877714,"version":"3.40.3"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,7,19]],"date-time":"2012-07-19T00:00:00Z","timestamp":1342656000000},"content-version":"vor","delay-in-days":8204,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[1990,2]]},"abstract":"<jats:p><jats:list list-type=\"explicit-label\"><jats:list-item><jats:p>The effect of kappa (\u03ba) opioid receptor activation on the increase in arginine vasopressin (AVP) secretion evoked by two acute and quite different stimuli (i.e., haemorrhage and osmotic stimulus due to hypertonic saline infusion) were evaluated in conscious Long\u2010Evans rats, by use of U\u201062066E, a highly selective \u03ba\u2010opioid receptor agonist, and MR2266, an opioid receptor antagonist with some selectivity for \u03ba\u2010receptors.<\/jats:p><\/jats:list-item><jats:list-item><jats:p>An acute haemorrhage, which reduced the mean blood pressure by approximately 50%, resulted in a large increase in the plasma AVP (pAVP) levels of control rats. However, the administration of U\u201062066E (0.2 mg kg<jats:sup>\u22121<\/jats:sup>or 2.0 mg kg<jats:sup>\u22121<\/jats:sup>) reduced the increase due to haemorrhage in a dose\u2010dependent manner. In contrast, concomitant administration of 2.0 mg kg<jats:sup>\u22121<\/jats:sup>of MR2266 with U\u201062066E significantly attenuated the inhibition of pAVP levels produced by U\u201062066E 2.0 mg kg<jats:sup>\u22121<\/jats:sup>.<\/jats:p><\/jats:list-item><jats:list-item><jats:p>Hypertonic saline infusion (5% hypertonic saline solution at a rate of 0.24 ml kg<jats:sup>\u22121<\/jats:sup>min<jats:sup>\u22121<\/jats:sup>for 10 min) caused the elevation of plasma osmolality (pOsm) from 294.0 \u00b1 1.6 mosmol kg<jats:sup>\u22121<\/jats:sup>to 304.4 \u00b1 1.9 mosmol kg<jats:sup>\u22121<\/jats:sup>, simultaneously resulting in a significant increase in pAVP levels from 2.34 \u00b1 0.28 pg ml<jats:sup>\u22121<\/jats:sup>to 4.54 \u00b1 0.51 pg ml<jats:sup>\u22121<\/jats:sup>. However, the administration of U\u201062066E (0.05 mg kg<jats:sup>\u22121<\/jats:sup>or 0.2 mg kg<jats:sup>\u22121<\/jats:sup>) reduced the osmotically induced increase in pAVP in a dose\u2010dependent manner although pOsm showed the same degree of increase as in controls. In contrast, concomitant administration of 0.2 mg kg<jats:sup>\u22121<\/jats:sup>of MR2266 with U\u201062066E significantly attenuated the inhibition of pAVP levels produced by U\u201062066E 0.2 mg kg<jats:sup>\u22121<\/jats:sup>, whereas pOsm showed the same degree of increase as in controls. No significant changes in the mean blood pressure of the respective groups were observed during this experiment.<\/jats:p><\/jats:list-item><jats:list-item><jats:p>It is suggested that the \u03ba\u2010opioid receptor activation reduces the increase in AVP secretion evoked by these two different stimuli and that the inhibitory involvement occurs in the neural lobe in the process of AVP secretion.<\/jats:p><\/jats:list-item><\/jats:list><\/jats:p>","DOI":"10.1111\/j.1476-5381.1990.tb14713.x","type":"journal-article","created":{"date-parts":[[2012,7,19]],"date-time":"2012-07-19T18:32:40Z","timestamp":1342722760000},"page":"384-388","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Inhibition of elevated arginine vasopressin secretion in response to osmotic stimulation and acute haemorrhage by U\u201062066E, a \u03ba\u2010opioid receptor agonist"],"prefix":"10.1111","volume":"99","author":[{"given":"K.","family":"Yamada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,19]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110146"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1985.sp015829"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.78.10.6543"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/282746a0"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1983.tb10547.x"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(85)90397-0"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.0090274"},{"key":"e_1_2_1_9_1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0022-3565(25)24939-4","article-title":"Central opioid receptors and baroreflex control of sympathetic and cardiovascular function","volume":"237","author":"GORDON F.J.","year":"1986","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)91346-6"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(77)90235-7"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(85)90431-5"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1979.sp013004"},{"key":"e_1_2_1_14_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-3565(25)22031-6","article-title":"Further study of kappa opioids on increased urination","volume":"227","author":"LEANDER J.D.","year":"1983","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"e_1_2_1_15_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0022-3565(25)39074-9","article-title":"Kappa agonist\u2010induced diuresis: Evidence for stereoselectivity, strain differences, independence of hydration variables and a result of decreased plasma vasopressin levels","volume":"242","author":"LEANDER J.D.","year":"1987","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0143-4179(84)90049-0"},{"key":"e_1_2_1_17_1","first-page":"H25","article-title":"Role of angiotensin II, \u03b1\u2010adrenergic system, and arginine vasopressin on arterial pressure in rat","volume":"246","author":"PALLER M.S.","year":"1984","journal-title":"Am. J. Physiol"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1987.tb02882.x"},{"key":"e_1_2_1_19_1","first-page":"F321","article-title":"Osmotic and non\u2010osmotic control of vasopressin release","volume":"236","author":"SCHRIER R.W.","year":"1979","journal-title":"Am. J. Physiol"},{"key":"e_1_2_1_20_1","first-page":"149","volume-title":"Disturbances in Body Fluid Osmolality","author":"SCHRIER R.W.","year":"1877"},{"key":"e_1_2_1_21_1","first-page":"243","volume-title":"Handbook of Physiology","author":"SHARE L.","year":"1974"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000169792"},{"key":"e_1_2_1_23_1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0022-3565(25)32986-1","article-title":"Studies on the nature and mechanism of diuretic activity of the opioid analgesic ethyketazocine","volume":"220","author":"SLIZGI G.R.","year":"1982","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cne.901060104"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.1947.0037"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.6121376"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.6648526"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90495-0"},{"key":"e_1_2_1_29_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1042\/cs0760013","article-title":"Interrelationship between urinary kallikrein\u2010kinins and arginine vasopressin in man","volume":"76","author":"YAMADA K.","year":"1989","journal-title":"Clin. Sci"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2858918"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90625-3"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5381.1990.tb14713.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.1990.tb14713.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T23:21:11Z","timestamp":1743808871000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5381.1990.tb14713.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1990,2]]}},"alternative-id":["10.1111\/j.1476-5381.1990.tb14713.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5381.1990.tb14713.x","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"type":"print","value":"0007-1188"},{"type":"electronic","value":"1476-5381"}],"subject":[],"published":{"date-parts":[[1990,2]]},"assertion":[{"value":"2012-07-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}